Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 3/20 | 0.41 |
| ▸ | CYP8B1 | Q9UNU6 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.35 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1233327 | 0.92 | MCHR1 (0.44) | MCHR1PRMT5 | |
| SCHEMBL1231771 | 0.87 | MCHR1 (0.50) | MCHR1PRMT5TLR7 | |
| Hydrochloric Acid SCHEMBL1232748 | 0.86 | MCHR1 (0.49) | MCHR1PRMT5TLR7 | |
| SCHEMBL1232966 | 0.78 | MCHR1 (0.49) | MCHR1PRMT5 | |
| SCHEMBL1233426 | 0.77 | TLR9 (0.42) | CYP8B1PRMT5TLR7 | |
| SCHEMBL1233029 | 0.76 | TLR7 (0.37) | MCHR1PRMT5TLR7TLR8 | |
| SCHEMBL1231794 | 0.75 | TLR9 (0.44) | CYP8B1PRMT5TLR7 | |
| SCHEMBL311081 | 0.75 | PRKDC (0.43) | PRMT5ALDH1A1 | |
| Hydrochloric Acid SCHEMBL1233122 | 0.75 | TLR7 (0.40) | TLR7TLR8KDM4EALDH1A1CYP1A2 | |
| SCHEMBL1233364 | 0.73 | PRMT5 (0.39) | MCHR1PRMT5TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7888349-B2 | Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-02-15 | — | — | US | disclosed |
| US-20070167476-A1 | Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds | 3M INNOVATIVE PROPERTIES COMPANY | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167476-A1 | Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds | IL4, IL2, IL5 | MCHR1 2512/4885CYP8B1 3218/4885PRMT5 630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.